Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 14489
Sealed predictions
- PCBD2 in dopamine neurons, braak+0.26 (p 0.498) → +0.21 (p 0.589)receipt 14496
Swarm cases
receipt 14496: PCBD2 in dopamine neurons, braak
- power
- full sample +0.19 (p 0.450, n 18), 95% CI -0.30 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.23 (p 0.365, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.21 (p 0.413, n 18). could be the mix.
- skeptic
- leave-one-out range +0.09 to +0.35, sign flips 0; without severely affected donors +0.19 (p 0.450, n 18). fragile.
- cell type
- strongest in microglia: +0.65 (p 0.0037, n 18) vs +0.19 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PCBD2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up PCBD2 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.53 p 0.062 (needs p < 1.6e-4)
Receipts
loading the receipts